Cambridge, Massachusetts, USA, April 21, 2026

In a major advancement for targeted cancer therapy, Nuvalent, Inc. has announced the presentation of pivotal data from its ALKOVE-1 Phase 1/2 clinical trial evaluating neladalkib, an investigational ALK-selective inhibitor, in patients with advanced ALK-positive non-small cell lung cancer (NSCLC). The data will be presented at the prestigious 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the company’s progress in addressing treatment resistance in oncology. Alongside this, Nuvalent will also share preliminary findings for zidesamtinib, a ROS1-selective inhibitor, reinforcing its growing pipeline of precision oncology therapies designed to overcome resistance and improve outcomes in difficult-to-treat cancers.

Neladalkib Targets Resistance in ALK+ Lung Cancer

A key highlight of the announcement is the clinical progress of neladalkib, a next-generation therapy specifically engineered to overcome resistance seen with existing ALK inhibitors. Many patients with ALK-positive NSCLC eventually develop resistance to first-, second-, and third-generation treatments, limiting long-term effectiveness. Neladalkib has been designed with brain-penetrant properties, enabling it to address central nervous system (CNS) metastases, a common complication in advanced lung cancer.

Importantly, the therapy demonstrates activity against treatment-emergent ALK mutations, including challenging mutations such as G1202R, which are often associated with poor prognosis. The drug has already received Breakthrough Therapy Designation and Orphan Drug Designation from the U.S. FDA, emphasizing its potential to address significant unmet medical needs in oncology.

Zidesamtinib Expands Precision Oncology Pipeline

Advertisement

cGxPJobs Banner

In addition to neladalkib, Nuvalent is advancing zidesamtinib, a highly selective ROS1 inhibitor aimed at treating patients with ROS1-positive cancers, including those who have developed resistance to current therapies. Preliminary data from the ARROS-1 Phase 1/2 trial will be presented at ASCO, focusing on patients with advanced ROS1-positive solid tumors beyond NSCLC.

Similar to neladalkib, zidesamtinib is designed for CNS penetration and to avoid off-target effects associated with TRK inhibition, which can lead to adverse neurological events. Notably, the U.S. FDA has accepted Nuvalent’s New Drug Application (NDA) for zidesamtinib in previously treated ROS1-positive NSCLC, with a PDUFA target action date of September 18, 2026, marking a critical regulatory milestone for the company.

Strategic Impact on Oncology Drug Development

Nuvalent’s dual presentation at ASCO underscores its strategic focus on structure-based drug design and kinase-targeted therapies, positioning the company at the forefront of next-generation precision oncology. By addressing key limitations of existing therapies—such as drug resistance, CNS metastases, and adverse side effects—Nuvalent aims to deliver more durable and effective treatment options for cancer patients.

The company’s pipeline reflects a broader industry trend toward highly selective, mutation-targeted therapies that can provide personalized treatment approaches in oncology. With both neladalkib and zidesamtinib demonstrating promising clinical profiles, Nuvalent is strengthening its role in shaping the future of lung cancer treatment and beyond.

Overall, the upcoming ASCO presentations represent a pivotal moment for Nuvalent, showcasing its ability to translate scientific innovation into clinical impact. As the oncology landscape continues to evolve, therapies like neladalkib and zidesamtinib could redefine treatment paradigms for patients with resistant and metastatic cancers, offering renewed hope through precision medicine advancements.

Source: Nuvalent press release